当前位置:首页 - 行情中心 - 东方生物(688298) - 财务分析 - 现金流量表

东方生物

(688298)

  

流通市值:37.28亿  总市值:37.28亿
流通股本:2.02亿   总股本:2.02亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金736,404,636.62501,200,438.12277,921,807.02987,470,919.91
  收到的税费返还35,473,862.1325,505,202.7115,216,296.1241,852,899.04
  收到其他与经营活动有关的现金105,262,879.8382,939,391.240,016,546.0248,969,681.12
  经营活动现金流入小计877,141,378.58609,645,032.03333,154,649.161,078,293,500.07
  购买商品、接受劳务支付的现金350,710,233.42226,654,698.77120,192,921.96389,575,168.46
  支付给职工以及为职工支付的现金356,587,865.44250,468,005.95136,828,467.85517,655,491.53
  支付的各项税费30,175,604.0122,579,492.6317,015,589.4336,374,980.89
  支付其他与经营活动有关的现金225,147,204.54153,108,959.7388,226,426.12328,586,907.75
  经营活动现金流出小计962,620,907.41652,811,157.08362,263,405.361,272,192,548.63
  经营活动产生的现金流量净额-85,479,528.83-43,166,125.05-29,108,756.2-193,899,048.56
二、投资活动产生的现金流量:
  收回投资收到的现金315,138,400314,437,600202,390,502.41466,088,560.25
  取得投资收益收到的现金2,935,060.352,495,825.38443,327.749,285,727.17
  处置固定资产、无形资产和其他长期资产收回的现金净额178,903171,161.64,1052,615,756.22
  收到的其他与投资活动有关的现金81,649,189.980,559,378.879,989,111.181,625,094,230.21
  投资活动现金流入小计399,901,553.25397,663,965.78282,827,046.332,103,084,273.85
  购建固定资产、无形资产和其他长期资产支付的现金231,444,548.98187,233,055.15132,827,020.28307,667,970.63
  投资支付的现金355,055,540.04341,002,350.04245,826,933.25416,553,139.64
  取得子公司及其他营业单位支付的现金000-
  支付其他与投资活动有关的现金240,670,419.79889,241,200.37622,547,038.52801,262,146.68
  投资活动现金流出小计827,170,508.811,417,476,605.561,001,200,992.051,525,483,256.95
  投资活动产生的现金流量净额-427,268,955.56-1,019,812,639.78-718,373,945.72577,601,016.9
三、筹资活动产生的现金流量:
  吸收投资收到的现金186,000186,000186,0000
  其中:子公司吸收少数股东投资收到的现金186,000186,000186,000-
  取得借款收到的现金286,159,634.3221,460,708.364,117,005.3384,000,000
  收到其他与筹资活动有关的现金26,352,204.4130,490,201.7528,492,298.690
  筹资活动现金流入小计312,697,838.71252,136,910.0592,795,303.99384,000,000
  偿还债务支付的现金126,544,086.7995,797,012.3661,000,000510,060,000
  分配股利、利润或偿付利息支付的现金5,390,637.082,960,766.21,272,700.8341,117,451.2
  其中:子公司支付给少数股东的股利、利润00-34,405,757.37
  支付其他与筹资活动有关的现金36,674,303.516,874,254.652,585,593.3466,704,007.49
  筹资活动现金流出小计168,609,027.38105,632,033.2164,858,294.17617,881,458.69
  筹资活动产生的现金流量净额144,088,811.33146,504,876.8427,937,009.82-233,881,458.69
四、汇率变动对现金及现金等价物的影响-59,558,709.86-45,147,841.6-24,957,288.44-24,409,916.74
五、现金及现金等价物净增加额-428,218,382.92-961,621,729.59-744,502,980.54125,410,592.91
  加:期初现金及现金等价物余额1,635,685,891.791,635,685,891.791,635,685,891.791,510,275,298.88
  期末现金及现金等价物余额1,207,467,508.87674,064,162.2891,182,911.251,635,685,891.79
补充资料:
  净利润--232,060,997.06--597,405,207.55
  资产减值准备-13,558,090.52-199,366,343.14
  固定资产和投资性房地产折旧-51,653,529.68-99,727,986.03
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-51,653,529.68-99,727,986.03
  无形资产摊销-30,601,223.88-79,416,852.51
  长期待摊费用摊销-11,116,752.02-23,611,801.12
  处置固定资产、无形资产和其他长期资产的损失--1,121,234.68--1,748,605.93
  固定资产报废损失-8,417.02-80,190.48
  公允价值变动损失--1,245,811.82-1,596,613.77
  财务费用-82,609,804.8-14,961,338.09
  投资损失--11,913,758.29--8,681,541.5
  递延所得税-27,705,748.38-12,161,015.42
  其中:递延所得税资产减少-27,729,824.05-12,350,615.94
    递延所得税负债增加--24,075.67--189,600.52
  存货的减少-4,521,863.89--26,628,553.52
  经营性应收项目的减少-20,883,194.52--71,207,168.47
  经营性应付项目的增加--49,873,445.92-56,400,578
  其他-306,479.97--
  现金的期末余额-674,064,162.2-1,635,685,891.79
  减:现金的期初余额-1,635,685,891.79-1,510,275,298.88
  现金及现金等价物的净增加额--961,621,729.59-125,410,592.91
公告日期2026-10-292026-08-292026-04-292026-04-29
审计意见(境内)标准无保留意见
TOP↑